SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-123003"
 

Search: onr:"swepub:oai:DiVA.org:uu-123003" > Pyroglutamate Abeta...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases

Wirths, Oliver (author)
Bethge, Tobias (author)
Marcello, Andrea (author)
show more...
Harmeier, Anja (author)
Jawhar, Sadim (author)
Lucassen, Paul J (author)
Multhaup, Gerd (author)
Brody, David L (author)
Esparza, Thomas (author)
Ingelsson, Martin (author)
Uppsala universitet,Geriatrik
Kalimo, Hannu (author)
Uppsala universitet,Geriatrik
Lannfelt, Lars (author)
Uppsala universitet,Geriatrik
Bayer, Thomas A (author)
show less...
 (creator_code:org_t)
2009-10-13
2010
English.
In: Journal of neural transmission. - : Springer Science and Business Media LLC. - 0300-9564 .- 1435-1463. ; 117:1, s. 85-96
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The presence of Abeta(pE3) (N-terminal truncated Abeta starting with pyroglutamate) in Alzheimer's disease (AD) has received considerable attention since the discovery that this peptide represents a dominant fraction of Abeta peptides in senile plaques of AD brains. This was later confirmed by other reports investigating AD and Down's syndrome postmortem brain tissue. Importantly, Abeta(pE3) has a higher aggregation propensity, and stability, and shows an increased toxicity compared to full-length Abeta. We have recently shown that intraneuronal accumulation of Abeta(pE3) peptides induces a severe neuron loss and an associated neurological phenotype in the TBA2 mouse model for AD. Given the increasing interest in Abeta(pE3), we have generated two novel monoclonal antibodies which were characterized as highly specific for Abeta(pE3) peptides and herein used to analyze plaque deposition in APP/PS1KI mice, an AD model with severe neuron loss and learning deficits. This was compared with the plaque pattern present in brain tissue from sporadic and familial AD cases. Abundant plaques positive for Abeta(pE3) were present in patients with sporadic AD and familial AD including those carrying mutations in APP (arctic and Swedish) and PS1. Interestingly, in APP/PS1KI mice we observed a continuous increase in Abeta(pE3) plaque load with increasing age, while the density for Abeta(1-x ) plaques declined with aging. We therefore assume that, in particular, the peptides starting with position 1 of Abeta are N-truncated as disease progresses, and that, Abeta(pE3) positive plaques are resistant to age-dependent degradation likely due to their high stability and propensity to aggregate.

Keyword

Transgenic mice
Arctic mutation
Swedish mutation
Presenilin-1 mutation
Sporadic Alzheimer's disease
Pyroglutamate Abeta
Biacore
Antibody specificity
MEDICINE
MEDICIN

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view